Your session is about to expire
← Back to Search
LY3361237 for Lupus
Study Summary
This trial will study a potential new treatment for lupus. It will last up to 34 weeks and involve up to 15 visits.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Placebo
- Group 2: LY3361237
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards are associated with administering LY3361237 to patients?
"The safety of LY3361237 has been estimated to be a 2 out of 3 on the Power scale, as this is currently in Phase 2 trials which lacks efficacy data but does indicate some degree of safety."
Could you provide information about the various centers in town that are conducting this medical trial?
"Currently, 23 clinical sites are opening recruitment for this trial. Patients can find a centre near them in Houston, Katy, or Huntington Beach as well as other locations. It is suggested to select the site nearest you so that commuting demands may be minimized if one decides to partake in the study."
Could I be a suitable candidate for this trial?
"This experiment is looking to enrol 90 people with Libman-Sacks disease, aged between 18 and 65. Moreover, all applicants must comply with the European League Against Rheumatism (EULAR) or American College of Rheumatology (ACR) 2019 classification criteria for SLE which requires a score of 10 points or more, as well as present a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 at screening day 1 and this same index's score needs to be at least 4 when excluding laboratory values on randomization Day 2."
Is the eligibility criteria for this research study limited to those under 60 years of age?
"Enrollment in this trial requires that patients are above the legal age of consent and below 65 years old."
How many volunteers are participating in this medical trial?
"The sponsor of this study, Eli Lilly and Company, are seeking 90 participants that adhere to the set inclusions criteria. The trial will be conducted at Houston Rheumatology & Arthritis Specialists in Katy, California and Newport Huntington Med Grp in Huntington Beach, Arizona."
Is this trial taking on new participants at the moment?
"Affirmative. Per the data hosted on clinicaltrials.gov, this medical trial is currently in its recruitment phase. This study was initially posted on March 7th 2022 and has been recently modified as of November 22nd 2022. Ninety patients need to be enrolled among a total of 23 sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger